Tyler Zeronda - 18 Jun 2021 Form 3 Insider Report for VYNE Therapeutics Inc. (VYNE)

Role
Interim CFO
Signature
/s/ Mutya Harsch, attorney-in-fact for Tyler Zeronda
Issuer symbol
VYNE
Transactions as of
18 Jun 2021
Net transactions value
$0
Form type
3
Filing time
21 Jun 2021, 17:19:13 UTC
Next filing
02 Jul 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding VYNE Common Stock 23,395 18 Jun 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding VYNE Stock Option 18 Jun 2021 Common Stock 13,504 $5.92 Direct F2
holding VYNE Stock Option 18 Jun 2021 Common Stock 4,375 $10.68 Direct F3
holding VYNE Stock Option 18 Jun 2021 Common Stock 9,375 $7.80 Direct F4
holding VYNE Stock Option 18 Jun 2021 Common Stock 18,834 $6.68 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This amount includes 18,853 shares underlying unvested restricted stock units that will vest over four years following the date of grant.
F2 The shares subject to the option vest over a period of 4 years. 25% of the shares subject to the option vested on June 30, 2020 and 6.25% of the shares vest on the last day of each quarter thereafter.
F3 The shares subject to the option vest over a period of 4 years. 25% of the shares subject to the option vested on March 31, 2021 and 6.25% of the shares will vest on the last day of each quarter thereafter.
F4 The shares subject to the option vest over a period of 4 years. 25% of the shares subject to the option will vest on June 30, 2021 and 6.25% of the shares will vest on the last day of each quarter thereafter.
F5 The shares subject to the option vest over a period of 4 years. 25% of the shares subject to the option will vest on March 31, 2022 and 6.25% of the shares will vest on the last day of each quarter thereafter.

Remarks:

The reporting person was not granted any additional awards in connection with his appointment as interim CFO of the Issuer.